Literature DB >> 19210501

Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis.

Y B Brauchli1, S S Jick, M Miret, C R Meier.   

Abstract

BACKGROUND: Systemic inflammation may increase the risk for cardiovascular diseases in patients with psoriasis, but data on this risk in patients with early psoriasis are scarce.
OBJECTIVES: To assess and compare the risk of developing incident myocardial infarction (MI), stroke or transient ischaemic attack (TIA) between an inception cohort of patients with psoriasis and a psoriasis-free population.
METHODS: We conducted an inception cohort study with a nested case-control analysis within the U.K.-based General Practice Research Database. The study population encompassed 36,702 patients with a first-time recorded diagnosis of psoriasis 1994-2005, matched 1 : 1 to psoriasis-free patients. We assessed crude incidence rates (IRs) and applied conditional logistic regression to obtain odds ratios (ORs) with 95% confidence intervals (CIs).
RESULTS: Overall, the IRs of MI (n = 449), stroke (n = 535) and TIA (n = 402) were similar among patients with or without psoriasis. However, the adjusted OR of developing MI for patients with psoriasis aged < 60 years was 1.66 (95% CI 1.03-2.66) compared with patients without psoriasis, while the OR for patients aged >or= 60 years was 0.99 (95% CI 0.77-1.26). The adjusted ORs of developing MI for patients of all ages with <or= 2 or > 2 prescriptions/year for oral psoriasis treatment were 2.48 (95% CI 0.69-8.91) and 1.39 (95% CI 0.43-4.53), with a similar finding for stroke and TIA.
CONCLUSIONS: The risk of developing a cardiovascular outcome was not materially elevated for patients with early psoriasis overall. In subanalyses, however, there was a suggestion of an increased (but low absolute) MI risk for patients with psoriasis aged < 60 years, mainly with severe disease.

Entities:  

Mesh:

Year:  2009        PMID: 19210501     DOI: 10.1111/j.1365-2133.2008.09020.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  51 in total

1.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.

Authors:  N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2011-02-03       Impact factor: 9.302

2.  Psoriasis and cardiovascular risk: strength in numbers, part II.

Authors:  Joel M Gelfand; Nehal N Mehta; Sinéad M Langan
Journal:  J Invest Dermatol       Date:  2011-05       Impact factor: 8.551

3.  Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women.

Authors:  Shaowei Wu; Wen-Qing Li; Jiali Han; Qi Sun; Abrar A Qureshi
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

4.  Genetic Epidemiology of Psoriasis.

Authors:  Rashmi Gupta; Maya G Debbaneh; Wilson Liao
Journal:  Curr Dermatol Rep       Date:  2014-03

5.  Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.

Authors:  Nehal N Mehta; YiDing Yu; Babak Saboury; Negar Foroughi; Parasuram Krishnamoorthy; Anna Raper; Amanda Baer; Jules Antigua; Abby S Van Voorhees; Drew A Torigian; Abass Alavi; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2011-05-16

Review 6.  Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.

Authors:  Giulia Ganzetti; Anna Campanati; Elisa Molinelli; Annamaria Offidani
Journal:  World J Cardiol       Date:  2016-02-26

7.  Risk and predictors of cardiovascular disease in psoriasis: a population-based study.

Authors:  Hilal Maradit-Kremers; Ross A Dierkhising; Cynthia S Crowson; Murat Icen; Floranne C Ernste; Marian T McEvoy
Journal:  Int J Dermatol       Date:  2013-01       Impact factor: 2.736

8.  Psoriasis and cardiovascular risk: strength in numbers.

Authors:  Joel M Gelfand; Rahat S Azfar; Nehal N Mehta
Journal:  J Invest Dermatol       Date:  2010-04       Impact factor: 8.551

9.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Authors:  Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

Review 10.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.